Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave

Click to increase image sizeClick to decrease image size

Acknowledgments

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

P.A.R. is supported by NHLBI K08 HL146943, an ATS Foundation/Boehringer Ingelheim Research Fellowship in ATS, and by the Respiratory Health Association.

The analyses described in this publication were conducted with data or tools accessed through the NCATS N3C Data Enclave (ncats.nih.gov/n3c/about) and supported by NCATS U24 TR002306. This research was possible because of the patients whose information is included within the data and the organizations and scientists who have contributed to the on-going development of this community resource: doi.org/10.5281/zenodo.3979622.

Disclosure

Dr Ravi Kalhan reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, personal fees from CVS Caremark, outside the submitted work.

Dr Paul A Reyfman reports personal fees from Medscape, personal fees from Guidepoint, and salary from MSD, outside the submitted work. The authors report no other conflicts of interest in this work.